Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects

1. BoffitoM,KurowskiM,KruseGet al. Atazanavir enhancessaquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291–7. 2. BoffitoM,MaitlandD,SamarasingheYetal. Thepharmacokineticsof HIV protease inhibitor combinations. Curr Opin infect Dis 2005; 18: 1–7. 3. Peytavin G, Dominguez S, Lamotte C et al. Minimization of the triple reciprocal lopinavir/ritonavir/amprenavir (LPV/RTV/APV) interaction by low-dose fluconazole (FCZ) in experienced HIV-1-infected patients (Pts) in the Lopigen Prospective Study. In: Abstracts of the Second IAS Conference on HIV Pathogenesis and Treatment, Paris, 2003. Abstract 864. Antivir Ther 2003; 8 Suppl 1: S428. 4. Koks CH, Crommentuyn KM, Hoetelmans RM et al. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1infected individuals. Br J Clin Pharmacol 2001; 51: 631–5. 5. Van Heeswijk R, Sabo JP, MacGregor TR et al. The effect of tipranavir/ritonavir 500/200 mg bid (TPV/r) on the pharmacokinetics of fluconazole in healthy volounteers. In: Abstracts of the Fifth International Workshop on Clinical Pharmacology in HIV Therapy, Rome, 2004. Abstract 20, poster 4.8. 6. Jackson KA, Rosenbaum SE, Kerr BM et al. A population pharmacokineticanalysisofnelfinavirmesylate inhuman immunodeficiencyvirusinfected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2000; 44: 1832–7. 7. Hirani VN, Raucy JL, Lasker JM. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab Dispos 2004; 32: 1462–7. 8. NiwaT,ShiragaT,TakagiA.Effect of antifungaldrugsoncytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005; 28: 1805–8.